The venom obtained from Okinawan box-jellyfish (Habu-kurage), Chiropsalmus quadrigatus, produced increases in contractions of isolated rat right atrial preparations in a concentration-dependent manner without changes in a spontaneous beating rate. These increases in contractions were significantly inhibited by diltiazem and did not show tachyphylaxis. The venom also produced increases in contractions of isolated rat aortic ring preparations (endothelium-intact) in a concentration-dependent fashion, which were reproducible with repeated application and were significantly inhibited by diltiazem or heating. These increases in vascular contractions were weakened in endothelium-denuded preparations, and almost abolished in a calcium-free medium. On the other hand, the venom at higher concentrations diminished contractions of both myocardial and vascular preparations and did not show reproducibility. These results suggest that the Habu-kurage venom is heat-labile and may increase contractions of cardiac muscle and aortic smooth muscle by increasing calcium influx into muscle cells, and that the venom at higher concentrations may produce dysfunction of muscle contractile systems due to calcium overload.
Many cases of stings by the box-jellyfish, Chironex fleckeri, have been reported in Australia 1-3 . This has prompted intense studies on the venom of Chironex fleckeri, using pharmacological, biochemical and clinical approaches [4] [5] [6] [7] . Chiropsalmus quadrigatus is a closely related species of Chironex fleckeri and native to Okinawa, Japan. The Okinawan box-jellyfish (also called "Habu-kurage" in Japanese) is known to be associated with dozens of cases of stings each year. Several infant deaths from stings of Chiropsalmus quadrigatus have been reported 8 . Although an effective antivenom therapy has been developed in Australia to neutralize Chironex fleckeri venom, there have been no studies on the venom of the Okinawan box-jellyfish and effective therapy has not been established. The venom of marine animals differs between species and its potency and efficacy vary according to habitat.
The present study was designed to clarify some actions of Habu-kurage venom on the cardiovascular system. For this purpose, the pharmacological actions of the crude venom of Habu-kurage on isolated rat myocardium and vascular smooth muscle were examined.
MATERIALS AND METHODS
This study was carried out following the Guidelines for Animal Experimentation of the University of the Ryukyus, and the protocol was approved by the Animal Care and Use Committee of the University of the Ryukyus.
Preparation of Habu-kurage venom
Live specimens of Habu-kurage were caught in coastal waters of Okinawa, Japan, and taxonomic examination was done by a marine biologist at the University of the Ryukyus. Adult Habu-kurage tentacles were used and prepared by reference to the paper of Wiltshire et al 9 .
Tentacles were cut off from five Habu-kurage bodies and frozen at -30°C until use. Nematocysts were prepared at 4°C by grinding the thawed tentacles (about 200 g) in saline (500 ml). The nematocysts in saline were then kept for 6 to 24 hours, and decanted to remove contaminants. Decantation was repeated several times and a nematocyst suspension was obtained. The suspension was kept at -30°C before purification. In order to refine the nematocyst venom, frozen suspension was resuspended in saline, and homogenized in a glass-homogenizer at 4°C for 30 minutes. It was then centrifuged at 3,000 G at 4°C for 10 minutes and strained through a 100 µm filter to remove the residue. The filtrate was used as the Habu-kurage venom, and the venom concentration was determined by the method of Lowry et al 10 and expressed as protein content/filtrate (µg/ml).
Experiments on isolated rat right atrial preparations
Male Sprague-Dawley rats weighing 250 to 300 g were anaesthetized with ether, and the chest was opened by a midsternal thoracotomy. Immediately after the heart was removed, it was placed in a petri dish containing oxygenated Krebs-Henseleit solution of the following composition: NaCl 120 mM, KCl 4.80 mM, CaCl 2 1.25 mM, MgSO 4 1.20 mM, KH 2 PO 4 1.20 mM, NaHCO 3 25.0 mM and glucose 11.0 mM. The right atrium was carefully dissected from the heart and the remaining fat and aorta were trimmed off. The aorta was used in another experiment mentioned below. This right atrial preparation was suspended in a 20 ml organ bath filled with Krebs-Henseleit solution, which was maintained at 37°C, pH 7.4 and continuously aerated with a gas mixture of 95% O 2 and 5% CO 2 . One end of the atrium was attached to a tissue-holder, and the other end was connected to an isometric force-displacement transducer (Nihon-kohden, TB-611T, Tokyo, Japan) in order to measure the contractile force of the preparation. Krebs-Henseleit solution in the organ bath was changed every 15 minutes, and the preparation was allowed to equilibrate for one hour. The load to the preparation was adjusted to 500 mg and main-tained at this level throughout the experiment. Beating rate in the right atrium was continuously counted by a cardiotachometer (Nihon-kohden, AT-600 G) triggered by the developed force of the atrium. Force development and beating rate of contraction of the preparation were recorded on a heatpen writing polygraph (Nihon-kohden, WT-685G).
Experiments on isolated rat aortic ring preparations
This experiment was performed using the aorta, which was trimmed off from the heart as mentioned above. From this aorta, ring preparations with and without endothelium of about 2.0 mm width were prepared. The preparation was mounted in an organ bath containing 20 ml Krebs-Henseleit solution maintained at 37°C, pH 7.4 and bubbled with 95% O 2 and 5% CO 2 , which was changed every 15 minutes. Isometric tension development of the preparation was measured by a force-displacement transducer (Nihon-kohden, TB-611T), and the resting tension was adjusted to an optimum of 1,000 mg. The preparation was equilibrated for 90 minutes, and then KCl at 30 mM was added to confirm contractility of the preparation. Changes in tension developed were recorded on a heat-pen writing polygraph (Nihonkohden, WT-685 G).
Drugs
Drugs used in this study were as follows: phentolamine mesylate (Novartis Pharma, Tokyo, Japan), ethyleneglycol-bis-(β-amino-ethylether)-N,N,N',N'tetra-acetic acid (EGTA: Wako, Tokyo, Japan) and diltiazem hydrochloride (Tanabe Pharmaceutical Co., Ltd., Osaka, Japan). All other chemicals were of analytical reagent grade.
Statistical analysis
All experimental data were represented as the mean±SEM and analyzed by Student's t test, and statistical significance was defined as a P value less than 5%.
RESULTS

Experiments on isolated rat right atrial preparations
Habu-kurage venom (0.03-0.3 µg/ml) produced increases in contractile force of isolated rat right atrial preparations in a concentration-dependent fashion. At 1.0 µg/ml, it decreased the developed force, elevated the minimum level of myocardial contractions, and thereafter stopped the contractions (Figure 1 ). When responses of four preparations to Habu-kurage venom were calculated, the elevation of minimum level of myocardial contractions reached 80 ±20 mg after applications of the venom at a con-centration of 1.0 µg/ml (Figure 2A ). In these four preparations to which the venom (0.03-1.0 µg/ml) was first applied, the second application of the venom at the same concentrations after 20 minutes of washingout produced markedly weaker responses. However, in another four atrial preparations to which Habukurage venom (0.03-0.3 µg/ml) was first applied, repeated application of the venom at the same concentrations did not produce any significantly different response from the first application ( Figure 2B ).
In another three atrial preparations exposed to Habu-kurage venom (0.03-0.3 µg/ml), diltiazem at 0.1 µM inhibited the venom-induced increases in contractile force; the inhibition on the effect of the venom at 0.3 µg/ml was statistically significant ( Figure  3A ). In these preparations, a spontaneous beating rate averaging about 270 beats/min was not changed after applications of the Habu-kurage venom or after diltiazem ( Figure 3B ).
Experiments on isolated rat aortic ring preparations
Habu-kurage venom (0.1-3.0 µg/ml) increased isometric tension development of aortic ring preparations (endothelium-intact) in a concentrationdependent manner. However, at 10.0 µg/ml, the venom slightly lessened the developed tension ( Figure 4A ). In other preparations in which tension developments were examined with venom concentrations of 0.1 to 1.0 µg/ml, the second or the third application of the venom did not produce any significantly different response from the first application ( Figure 4B ).
In aortic preparations without endothelium, the 572 M. SAKANASHI, T. MATSUZAKI ET AL increases in developed tension were significantly weaker than those in preparations with endothelium ( Figure 5A ). Habu-kurage venom at 0.1-3.0 µg/ml, which was heated to 40°C for 10 minutes, induced a slightly weaker tension development of aortic preparations with endothelium than the non-heated venom (the control), although differences were not statistically significant. When the venom was heated to 50°C for 10 minutes, its effect was abolished at all concentrations ( Figure 5B) .
In calcium-free Krebs-Henseleit solution including EGTA at 1.0 mM, the effects of Habu-kurage venom (0.1-3.0 µg/ml) on aortic preparations were markedly inhibited and only a small increase in developed tension was observed as shown in Figure 6A . Diltiazem at 1.0 µM significantly inhibited the increases in developed tension by the venom (0.1 to 3.0 µg/ml). Diltiazem at 3.0 µM further inhibited the venominduced responses ( Figure 6B ).
Phentolamine at 1.0 µM did not influence the increases in developed tension of the preparations (data not shown).
DISCUSSION
The results showed that increases in contractile force of isolated rat right atrial preparations were obtained with applications of Habu-kurage venom. However, the venom at a higher concentration (1.0 µg/ml) decreased the contractions and then ceased myocardial contractions along with an elevation of minimum level of contractions. These observations suggest the possibilities that Habu-kurage venom will increase the calcium influx into myocardial cells and that the venom at a higher concentration may stop the myocardial contraction through calcium-overload. This phenomenon has also been reported with the venom of Chironex fleckeri, a boxjellyfish similar to Habu-kurage 11 and with the venom of Portuguese man-of-war, Physalia physalis 12, 13 .
Furthermore, these data showed that the increases in right atrial contractile force provoked by Habukurage venom were significantly inhibited by diltiazem, an L-type calcium antagonist 14, 15 . This result supports a hypothesis that venom-induced increases in atrial contractions are due to increases in calcium influx into myocardial cells, probably via voltage-dependent calcium channels. However, Mustafa et al 11 have reported different experimental results in which increases in contraction of isolated ferret papillary muscles induced with Chironex fleckeri venom were not inhibited by nifedipine, a similar L-type calcium antagonist 14, 15 . Discrepancies between the present results and their report may be caused by differences in the venom, the animals, the tissues and/or the calcium antagonist used. Nifedipine used in their study is known to have selectivity for vasculature, while diltiazem used in this study is believed to act on both myocardium and vasculature 16 . Additionally, the efficacy of another L-type calcium antagonist, verapamil 14, 15 , against the actions of Chironex fleckeri venom, has yielded conflicting results indicating that the drug was effective 7,17 and ineffective 18, 19 .
In this study, increases in atrial contractile force with repeated application of Habu-kurage venom at low concentrations were reproducible, indicating a lack of tachyphylaxis. Preparations once exposed with a high concentration of venom (1.0 µg/ml), however, showed weaker contractile responses to the second application of low concentrations. This suggests that myocardial contractile dysfunction may occur with a high concentration of the venom, through calciumoverload.
Spontaneous beating rates of right atrial preparations were not changed by the venom, suggesting that the pacemaker cells have a lower sensitivity to the venom than other myocardial cells. However, the reason for different sensitivities to the venom between the tissues was not studied and remains to be resolved.
The present data indicated that Habu-kurage venom (0.1-1.0 µg/ml) produced concentrationdependent increases in developed tension of isolated rat aortic preparations. As the second application of the venom induced similar responses to the first application, it is considered that the venom does not cause tachyphylaxis. However, the venom at a higher concentration (10.0 µg/ml) slightly lessened the developed tension, and these preparations exposed once to the venom at this high concentration did not reveal any contractile response to the second application. These results indicate that the Habu-kurage venom at higher concentrations may induce irreversible damage to the contractile system of aortic smooth muscles.
In endothelium-denuded aortic preparations, increases in developed tension with the venom were significantly weakened, leading to the hypothesis that the actions of the Habu-kurage venom may involve synthesis in endothelium and/or releasing from endothelium of vasoconstrictive substances such as endothelin I and/or angiotensin II 20 .
Increases in developed tension of aortic preparations were slightly diminished when the venom was heated to 40°C for 10 minutes, and absent when the venom was heated to 50°C for 10 minutes. This demonstrated that the Habu-kurage venom is heat labile.
In calcium-free Krebs-Henseleit solution, the Habu-kurage venom produced only a very slight increase in developed tension of aortic preparations. This observation suggests that the increase in vascular contraction due to the venom mainly depends on calcium influx into vascular smooth muscle cells from extracellular space. In addition, venom-induced increases in vasocontraction were significantly inhibited by diltiazem, an L-type calcium antagonist 14, 15 , showing that Habu-kurage venom will induce calcium influx into muscle cells via voltage-dependent calcium channels. Furthermore, it is speculated that the very slight contractile response in calcium-free medium may indicate a small calcium-releasing action of the venom from intracellular calcium storage sites.
Phentolamine, a non-selective α-adrenoceptor blocking agent 21 , at concentrations sufficient for α-adrenergic blockade in vitro 22 did not influence increases in developed tension of aortic preparations produced by the venom. This suggests that the calcium influx into vascular smooth muscle cells does not occur via receptor-operated calcium channels, and indirectly supports the hypothesis that the venom will induce calcium-influx into muscle cells via voltage-dependent calcium channels.
When the potency of Habu-kurage venom in isolated atrial preparations was compared with that in isolated aortic preparations obtained from an identical animal, definite increases in contraction were observed with the venom at a concentration of 0.03 µg/ml in atrial preparations and at 0.1 µg/ml in aortic preparations. Moreover, when repeated application of the venom produced diminution or abolition of contractile responses, the venom concentration of the first application reached 1.0 µg/ml in atrial preparations and 3.0 µg/ml in aortic preparations, respectively. Thus, the sensitivity of tissues to Habu-kurage venom is considered to be about three times higher in atrial preparations than in aortic preparations.
In conclusion, the present results show that Habukurage venom is heat-labile and may increase contractions of cardiac and aortic smooth muscle by increasing calcium influx into muscle cells via voltagedependent calcium channels. Higher concentrations of the venom will produce dysfunction of the muscular contractile system probably due to calcium overload; it is suggested that diltiazem, an L-type calcium antagonist, may reduce or prevent contractile dysfunction.
